Trial | NCT01636674  Report issue

Title

18F-FDG PET/CT and Molecular Tumor Characterisation for Staging and Follow-up of Colon Cancer
Value of 18F-Fluordeoxyglucose Positron Emission Tomography/ Computed Tomography and Molecular Tumor Characterisation in Preoperative Staging og Postoperative Control of Colon Cancer

  • Phase

    N/A

  • Study Type

    Interventional

  • Status

    Unknown status

  • Study Participants

    66
The investigators are investigating the usefulness of 18F-Fluordeoxyglucose Positron Emission Tomography/ Computed Tomography (18F-FDG PET/CT) for staging and follow-up of colon cancer. Furthermore, the investigators combine 18F-FDG PET findings with clinical and histopathological features, circulating tumor cell (CTC) analyses, tumor gene expression and measurements of circulating cancer biomarkers sUPAR, TIMP-1 and CEA in order to predict tumor recurrence.

The investigators hypothesis: The combination of functional imaging by 18F-FDG PET/CT and pre-existing and evolving molecular biomarkers will optimize tumor characterization, staging of disease and early detection of recurrence.
Study Started
Jul 31
2009
Primary Completion
Mar 31
2013
Anticipated
Study Completion
Mar 31
2013
Anticipated
Last Update
Jul 10
2012
Estimate

Other 18F-fluordeoxyglucose positron emission tomography/ computed tomography

18F-fluordeoxyglucose positron emission tomography/ computed tomography for preoperative staging and post-operative follow-up

Criteria 

Inclusion Criteria:

clinical or histological diagnosis of malignant clonic neoplasm (distance of more than 15 cm from anal ring)
18 years of age or older
written informed consent

Exclusion Criteria:

diabetes
known malignant disease other than colon cancer
known metastatic disease
impairment of renal function
allergy to CT contrast agents
body weight of more than 150 kg
claustrophobia
No Results Posted